Quantitative contrast enhanced ultrasound and ct assessment of tumor response to antiangiogenic therapy in rats

Ultrasound in Medicine and Biology

Volumn 33, Issue 2, 2007, Pages 235-245

  Pollard, Rachel E ^a   Broumas, Amy R ^b   Wisner, Erik R ^a   Vekich, Sylvia V ^c   Ferrara, Katherine W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antiangiogenic therapy; Contrast CT; Contrast ultrasound; Quantitative imaging

Indexed keywords

ANTIANGIOGENIC THERAPY; CONTRAST CT; CONTRAST ULTRASOUND; QUANTITATIVE IMAGING; SERUM DRUG LEVEL (SDL); TUMOR VIABILITY;

COMPUTERIZED TOMOGRAPHY; HISTOLOGY; IMAGE ANALYSIS; MAGNETIC PERMEABILITY; PARAMETER ESTIMATION; TUMORS;

ULTRASONIC IMAGING;

ANGIOGENESIS INHIBITOR; PLACEBO; SU 11657; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD FLOW; BREAST ADENOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; HISTOPATHOLOGY; IMAGING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE; TUMOR VASCULARIZATION; ULTRASOUND;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; BLOOD VOLUME; FEMALE; IMAGE ENHANCEMENT; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASM TRANSPLANTATION; ORGANIC CHEMICALS; RATS; RATS, INBRED F344; RECEPTOR PROTEIN-TYROSINE KINASES; REGIONAL BLOOD FLOW; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33846904162     PISSN: 03015629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ultrasmedbio.2006.07.036     Document Type: Article

References (37)

1. Aronen H.J., Cohen M.S., Belliveau J.W., Fordham J.A., and Rosen B.R. Ultrafast imaging of brain tumors. Top Magn Reson Imaging 5 1 (1993) 14-24
2. Arora N., Masood R., Zheng T., et al. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res 59 1 (1999) 183-188
3. Atiqur Rahman M., and Toi M. Anti-angiogenic therapy in breast cancer. Biomed Pharmacother 57 10 (2003) 463-470
4. Brasch R., and Turetschek K. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. Eur J Radiol 34 3 (2000) 148-155
5. Brasch R.C., Gossmann A., Helbich T.H., et al. Can a small-molecular gadolinium contrast agent be applied successfully with dynamic MRI to quantitatively define brain tumor microvascular responses to angiogenesis inhibition?. Acad Radiol 2 Suppl. 9 (2002) S326-S327
6. Brix G., Bahner M.L., Hoffmann U., Horvath A., and Schreiber W. Regional blood flow, capillary permeability, and compartmental volumes: measurement with dynamic CT-initial experience. Radiology 210 1 (1999) 269-276
7. Broumas A.R., Pollard R.E., Bloch S.H., et al. Contrast-enhanced computed tomography and ultrasound for the evaluation of tumor blood flow. Invest Radiol 40 3 (2005) 134-147
8. Burns P.N., Wilson S.R., and Simpson D.H. Pulse inversion imaging of liver blood flow: Improved method for characterizing focal masses with microbubble contrast. Invest Radiol 35 1 (2000) 58-71
9. Cenic A., Nabavi D.G., Craen R.A., Gelb A.W., and Lee T.Y. Dynamic CT measurement of cerebral blood flow: Validation study. AJNR Am J Neuroradiol 20 1 (1999) 63-73
10. Cenic A., Nabavi D.G., Craen R.A., Gelb A.W., and Lee T.Y. A CT method to measure hemodynamics in brain tumors: Validation and application of cerebral blood flow maps. AJNR Am J Neuroradiol 21 3 (2000) 462-470
11. Chomas J.E., Dayton P., Allen J., Morgan K., and Ferrara K.W. Mechanisms of contrast agent destruction. IEEE Trans Ultrason Ferroelectr Freq Control 48 1 (2001) 232-248
12. Chomas J.E., Pollard R.E., Sadlowski A.R., et al. Contrast-enhanced US of microcirculation of superficially implanted tumors in rats. Radiology 229 2 (2003) 439-446
13. Daldrup H., Shames D.M., Wendland M., et al. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: Comparison of macromolecular and small-molecular contrast media. AJR Am J Roentgenol 171 4 (1998) 941-949
14. Douglas M.L., Reid J.L., Hii S.I., Jonsson J.R., and Nicol D.L. Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide. BJU Int 89 6 (2002) 591-595
15. Esserman L., Hylton N., George T., and Weidner N. Contrast-enhanced magnetic resonance imaging to assess tumor histopathology and angiogenesis in breast carcinoma. Breast J 5 1 (1999) 13-21
16. Evelhoch J.L. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 10 3 (1999) 254-259
17. Ferrone M., and Motl S.E. Trastuzumab for the treatment of non-small-cell lung cancer. Ann Pharmacother 37 12 (2003) 1904-1908
18. Forsberg F., Shi W.T., and Goldberg B.B. Subharmonic imaging of contrast agents. Ultrasonics 38 1-8 (2000) 93-98
19. Freireich E.J., Gehan E.A., Rall D.P., Schmidt L.H., and Skipper H.E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50 4 (1966) 219-244
20. Garofalo A., Naumova E., Manenti L., et al. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin Cancer Res 9 9 (2003) 3476-3485
21. Hirata M., Sugawara Y., Fukutomi Y., et al. Measurement of radiation dose in cerebral CT perfusion study. Radiat Med 23 2 (2005) 97-103
22. Kiessling F., Boese J., Corvinus C., et al. Perfusion CT in patients with advanced bronchial carcinomas: A novel chance for characterization and treatment monitoring?. Eur Radiol 14 7 (2004) 1226-133
23. Krix M., Kiessling F., Vosseler S., et al. Sensitive noninvasive monitoring of tumor perfusion during antiangiogenic therapy by intermittent bolus-contrast power Doppler sonography. Cancer Res 63 23 (2003) 8264-8270
24. Laird A.D., Vajkoczy P., Shawver L.K., et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60 15 (2000) 4152-4160
25. Margolin K., Gordon M.S., Holmgren E., et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 19 3 (2001) 851-856
26. Miles K.A., Leggett D.A., and Bennett G.A. CT derived Patlak images of the human kidney. Br J Radiol 72 854 (1999) 153-158
27. Nabavi D.G., Cenic A., Henderson S., Gelb A.W., and Lee T.Y. Perfusion mapping using computed tomography allows accurate prediction of cerebral infarction in experimental brain ischemia. Stroke 32 1 (2001) 175-183
28. Netti P.A., Roberge S., Boucher Y., Baxter L.T., and Jain R.K. Effect of transvascular fluid exchange on pressure-flow relationship in tumors: A proposed mechanism for tumor blood flow heterogeneity. Microvasc Res 52 1 (1996) 27-46
29. Patlak C.S., Blasberg R.G., and Fenstermacher J.D. Graphical evaluation of blood-to-brain transfer constants from multiple- time uptake data. J Cereb Blood Flow Metab 3 1 (1983) 1-7
30. Pollard R.E., Garcia T.C., Stieger S.M., et al. Quantitative evaluation of perfusion and permeability of peripheral tumors using contrast-enhanced computed tomography. Invest Radiol 39 6 (2004) 340-349
31. Pollard R.E., Sadlowski A.R., Bloch S.H., et al. Contrast-assisted destruction-replenishment ultrasound for the assessment of tumor microvasculature in a rat model. Technol Cancer Res Treat 1 6 (2002) 459-470
32. Sadlowski A., Chomas J., and Pollard R. Mean flow rate and integrated perfusion estimates obtained with contrast-assisted ultrasound. IEEE Proceedings (2002) Munich, Germany
33. Sboros V., Moran C.M., Pye S.D., and McDicken W.N. Contrast agent stability: A continuous B-mode imaging approach. Ultrasound Med Biol 27 10 (2001) 1367-1377
34. Tiemann K., Veltmann C., Ghanem A., et al. The impact of emission power on the destruction of echo contrast agents and on the origin of tissue harmonic signals using power pulse-inversion imaging. Ultrasound Med Biol 27 11 (2001) 1525-1533
35. Traxler P. Tyrosine kinases as targets in cancer therapy-successes and failures. Expert Opin Ther Targets 7 2 (2003) 215-234
36. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 60 4 (2000) 970-975
37. Wei K., Jayaweera A.R., Firoozan S., et al. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 97 5 (1998) 473-483